Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106


End-Users' Product Preference Across Three Multipurpose Prevention Technology Delivery Forms: Baseline Results from Young Women in Kenya and South Africa.

Weinrib R, Minnis A, Agot K, Ahmed K, Owino F, Manenzhe K, Cheng H, van der Straten A.

AIDS Behav. 2018 Jan;22(1):133-145. doi: 10.1007/s10461-017-1911-6.


Young Women's Ratings of Three Placebo Multipurpose Prevention Technologies for HIV and Pregnancy Prevention in a Randomized, Cross-Over Study in Kenya and South Africa.

Minnis AM, Roberts ST, Agot K, Weinrib R, Ahmed K, Manenzhe K, Owino F, van der Straten A; TRIO Study Team.

AIDS Behav. 2018 Aug;22(8):2662-2673. doi: 10.1007/s10461-018-2078-5.


The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention.

van der Straten A, Agot K, Ahmed K, Weinrib R, Browne EN, Manenzhe K, Owino F, Schwartz J, Minnis A; TRIO Study Team.

J Int AIDS Soc. 2018 Mar;21(3):e25094. doi: 10.1002/jia2.25094.


Young Women's Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa.

Minnis AM, Browne EN, Boeri M, Agot K, van der Straten A, Ahmed K, Weinrib R, Mansfield C.

J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):394-403. doi: 10.1097/QAI.0000000000001945.


Multipurpose prevention technologies: products in development.

Friend DR, Clark JT, Kiser PF, Clark MR.

Antiviral Res. 2013 Dec;100 Suppl:S39-47. doi: 10.1016/j.antiviral.2013.09.030. Epub 2013 Nov 1. Review.


"We are not the same": African women's view of multipurpose prevention products in the TRIO clinical study.

Shapley-Quinn MK, Manenzhe KN, Agot K, Minnis AM, van der Straten A.

Int J Womens Health. 2019 Feb 7;11:97-107. doi: 10.2147/IJWH.S185712. eCollection 2019.


Lessons from reproductive health to inform multipurpose prevention technologies: don't reinvent the wheel.

Brady M, Manning J.

Antiviral Res. 2013 Dec;100 Suppl:S25-31. doi: 10.1016/j.antiviral.2013.09.019. Epub 2013 Nov 1. Review.


Interest in multipurpose prevention technologies to prevent HIV/STIs and unintended pregnancy among young women in the United States.

Hynes JS, Sales JM, Sheth AN, Lathrop E, Haddad LB.

Contraception. 2018 Mar;97(3):277-284. doi: 10.1016/j.contraception.2017.10.006. Epub 2017 Oct 18.


User evaluations offer promise for pod-intravaginal ring as a drug delivery platform: A mixed methods study of acceptability and use experiences.

Guthrie KM, Rosen RK, Vargas SE, Getz ML, Dawson L, Guillen M, Ramirez JJ, Baum MM, Vincent KL.

PLoS One. 2018 May 14;13(5):e0197269. doi: 10.1371/journal.pone.0197269. eCollection 2018.


Designing a multipurpose technology for acceptability and adherence.

Tolley EE, Morrow KM, Owen DH.

Antiviral Res. 2013 Dec;100 Suppl:S54-9. doi: 10.1016/j.antiviral.2013.09.029. Epub 2013 Nov 1. Review.


Prioritizing multipurpose prevention technology development and investments using a target product profile.

Romano J, Manning J, Hemmerling A, McGrory E, Holt BY.

Antiviral Res. 2013 Dec;100 Suppl:S32-8. doi: 10.1016/j.antiviral.2013.09.016. Epub 2013 Nov 1.


Insights for Implementation Science From 2 Multiphased Studies With End-Users of Potential Multipurpose Prevention Technology and HIV Prevention Products.

Minnis AM, Montgomery ET, Napierala S, Browne EN, van der Straten A.

J Acquir Immune Defic Syndr. 2019 Dec;82 Suppl 3:S222-S229. doi: 10.1097/QAI.0000000000002215.


The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa.

Quaife M, Terris-Prestholt F, Eakle R, Cabrera Escobar MA, Kilbourne-Brook M, Mvundura M, Meyer-Rath G, Delany-Moretlwe S, Vickerman P.

J Int AIDS Soc. 2018 Mar;21(3). doi: 10.1002/jia2.25064.


A strategic action framework for multipurpose prevention technologies combining contraceptive hormones and antiretroviral drugs to prevent pregnancy and HIV.

Young Holt B, Dellplain L, Creinin MD, Peine KJ, Romano J, Hemmerling A.

Eur J Contracept Reprod Health Care. 2018 Oct;23(5):326-334. doi: 10.1080/13625187.2018.1508650. Epub 2018 Sep 24.


Divergent Preferences for HIV Prevention: A Discrete Choice Experiment for Multipurpose HIV Prevention Products in South Africa.

Quaife M, Eakle R, Cabrera Escobar MA, Vickerman P, Kilbourne-Brook M, Mvundura M, Delany-Moretlwe S, Terris-Prestholt F.

Med Decis Making. 2018 Jan;38(1):120-133. doi: 10.1177/0272989X17729376. Epub 2017 Sep 1.


Engaging study participants in interpreting results: lessons from the TRIO study in Kenya and South Africa.

Agot K, Minnis AM, Manenzhe K, Browne EN, Ahmed K, Okello T, van der Straten A.

Int J Womens Health. 2019 Jul 12;11:395-403. doi: 10.2147/IJWH.S193905. eCollection 2019.


Acceptability and preferences for vaginal dosage forms intended for prevention of HIV or HIV and pregnancy.

Woodsong C, Holt JD.

Adv Drug Deliv Rev. 2015 Sep 15;92:146-54. doi: 10.1016/j.addr.2015.02.004. Epub 2015 Feb 19. Review.


Meaning-making matters in product design: users' sensory perceptions and experience evaluations of long-acting vaginal gels and intravaginal rings.

Rosen RK, van den Berg JJ, Vargas SE, Senocak N, Shaw JG, Buckheit RW Jr, Smith KA, Guthrie KM.

Contraception. 2015 Dec;92(6):596-601. doi: 10.1016/j.contraception.2015.08.007. Epub 2015 Aug 11.


Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study.

Luecke EH, Cheng H, Woeber K, Nakyanzi T, Mudekunye-Mahaka IC, van der Straten A; MTN-003D Study Team.

J Int AIDS Soc. 2016 May 30;19(1):20875. doi: 10.7448/IAS.19.1.20875. eCollection 2016.


Multipurpose prevention technologies for sexual and reproductive health: mapping global needs for introduction of new preventive products.

Schelar E, Polis CB, Essam T, Looker KJ, Bruni L, Chrisman CJ, Manning J.

Contraception. 2016 Jan;93(1):32-43. doi: 10.1016/j.contraception.2015.09.002. Epub 2015 Sep 16.

Supplemental Content

Support Center